Mützel V W
Arzneimittelforschung. 1976;26(7b):1487-92.
Two male normal subjects were each given 1 mg of 6alpha,9-difluoro-11beta-hydroxy-16alpha-methyl-21-valeryloxy-1,4-pregnadiene-3,20-dione1,2,4-3H (3H-diflucortolone valerate, Nerisona) by i.v. injection. The pharmacokinetics and biotransformation of the corticoid were examined by measurement of the total activity in the blood, plasma, urine and faeces and by thin-layer chromatographic analysis of the spectrum of the metabolites in plasma and urine. The compound is very rapidly degraded. No more intact ester was identifiable in the plasma 5 min after injection while, at the same time, 6alpha,9-difluoro-11beta,21-dihydroxy-16alpha-methyl-1,4-pregnadiene-3,20-dione (diflucortolone), the product of hydrolysis, was present in a concentration of 6-8 ng/ml plasma. The half-life of diflucortolone in the plasma was 4-5 h, that of the total 3H-steroids about 9 h. 80-40% of the 3H-steroids in the plasma were in unconjugated form. Besides diflucortolone and two unidentified metabolites chromatographic comparison demonstrated the presence of 6alpha,9-difluoro-21-hydroxy-16alpha-methyl-1,4-pregnadiene-3,11,20-trione (11-keto-diflucortolone) as a further metabolite in the plasma. The elimination was rapid and complete: by 24 h after injection approximately 56% of the dose had been eliminated with the urine and by 7 days after administration 98 and 93% of the dose had been recovered in urine and faeces. The ratio of elimination urine to faeces averaged 3:1. Within 48 h after the injection about 30% of the dose was eliminated in the form of unconjugated 3H-steroids, about 20% as 3H-steroid-glucuronides and about 10% as 3H-steroid-sulphates. Diflucortolone was demonstrable both in the unconjugated form and as glucuronide and 11-keto-diflucortolone as glucuronide and as sulphate. A total of 7 metabolites were characterized in the urine by means of chromatography.
两名男性正常受试者分别静脉注射1毫克6α,9 - 二氟 - 11β - 羟基 - 16α - 甲基 - 21 - 戊酰氧基 - 1,4 - 孕二烯 - 3,20 - 二酮1,2,4 - 3H(3H - 二氟可的索戊酸酯,Nerisona)。通过测定血液、血浆、尿液和粪便中的总活性,以及对血浆和尿液中代谢产物谱进行薄层色谱分析,研究了该皮质类固醇的药代动力学和生物转化。该化合物降解非常迅速。注射后5分钟血浆中已无法识别完整的酯,与此同时,水解产物6α,9 - 二氟 - 11β,21 - 二羟基 - 16α - 甲基 - 1,4 - 孕二烯 - 3,20 - 二酮(二氟可的索)在血浆中的浓度为6 - 8纳克/毫升。二氟可的索在血浆中的半衰期为4 - 5小时,总3H - 类固醇的半衰期约为9小时。血浆中80 - 40%的3H - 类固醇呈未结合形式。除二氟可的索和两种未鉴定的代谢产物外,色谱对比表明血浆中还存在另一种代谢产物6α,9 - 二氟 - 21 - 羟基 - 16α - 甲基 - 1,4 - 孕二烯 - 3,11,20 - 三酮(11 - 酮 - 二氟可的索)。消除迅速且完全:注射后24小时约56%的剂量随尿液排出,给药7天后98%和93%的剂量分别在尿液和粪便中回收。尿液与粪便的消除比例平均为3:1。注射后48小时内,约30%的剂量以未结合的3H - 类固醇形式排出,约20%以3H - 类固醇葡萄糖醛酸苷形式排出,约10%以3H - 类固醇硫酸盐形式排出。二氟可的索既可以未结合形式存在,也可以葡萄糖醛酸苷形式存在,11 - 酮 - 二氟可的索则以葡萄糖醛酸苷和硫酸盐形式存在。通过色谱法在尿液中总共鉴定出7种代谢产物。